Arlington Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
Arlington Partners's ARKG Position: Q3 2022 in Review
Arlington Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2022, closing a stake of 220 shares — an estimated $7K sold.
Arlington Partners first reported a position in ARKG in Q2 2022 and held it in 1 quarter. The position peaked at $7K in Q2 2022. 311 funds tracked by Wall St. Rank hold ARKG as of Q3 2022.
- Arlington Partners reported no remaining ARK Genomic Revolution ETF position as of Q3 2022 after selling out during the quarter.
- Arlington Partners sold 220 ARK Genomic Revolution ETF shares in Q3 2022, an estimated $7K.
- Arlington Partners first reported a position in ARK Genomic Revolution ETF in Q2 2022 and held it in 1 quarter.
- Arlington Partners's ARK Genomic Revolution ETF position peaked at $7K in Q2 2022.
- 311 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2022.
Based on Arlington Partners's 13F filing for Q3 2022, filed 28 Oct 2022.